Your session is about to expire
← Back to Search
Rivaroxaban + Ticagrelor for Atrial Fibrillation After Stent Placement (CAPITAL PCI AF Trial)
CAPITAL PCI AF Trial Summary
This trial is studying the combination of two potent drugs, ticagrelor and rivaroxaban, in AF patients receiving a stent placement, in order to gain insight into the management of these high-risk patients.
CAPITAL PCI AF Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCAPITAL PCI AF Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CAPITAL PCI AF Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have not completed a specific heart procedure called PCI.You are taking a blood thinner for a condition other than non-valvular atrial fibrillation.Your kidneys are not working well, based on a test called CrCl.You have had a procedure called PCI with stent placement.Atrial flutter can be considered as an equivalent to atrial fibrillation.Your CHADS-VASC score is less than 1.You are currently taking certain strong medications that can interact with the study drug.You are allergic or have bad reactions to rivaroxaban or ticagrelor.You have been diagnosed with atrial fibrillation using an ECG or other heart monitoring devices.You have a condition that makes it unsafe for you to take blood thinning medication.You have had a stroke in the past.You are in a state of severe heart failure when screened for the trial.You have a type of irregular heartbeats that doesn't get better with treatment when checked before joining the study.You have a serious liver disease or abnormal liver function test results.Your hemoglobin level is less than 90 grams per deciliter at screening.You have a serious illness that may result in living for less than 12 months.You have a planned coronary artery bypass grafting (CABG) surgery.You have a temporary irregular heartbeat caused by a fixable medical issue, like an overactive thyroid or recent surgery.You have been diagnosed with non-valvular atrial fibrillation within the past year, or more than a year ago if you have been taking oral anticoagulation therapy for at least 3 months before the procedure.You don't have a certain type of heart condition called non-valvular atrial fibrillation or a specific problem with your heart valve.
- Group 1: Ticagrelor and Rivaroxaban
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has this therapeutical procedure received FDA clearance?
"Since this is a Phase 3 trial, there is more safety data available for this treatment than others. Our team gives it a score of 3."
How many individuals are involed in this test?
"Unfortunately, this particular study is no longer admitting patients. Although, if you are still interested in atrial fibrillation research, there are 632 other studies and 104 trials that might be a better fit."
What are the primary purposes of this medication?
"Acute chest syndrome is often treated with this intervention. This particular treatment is also effective for thrombosis, prophylaxis of systemic embolism, and reducing cardiovascular mortality."
Share this study with friends
Copy Link
Messenger